1. Home
  2. OMER vs STKL Comparison

OMER vs STKL Comparison

Compare OMER & STKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$11.36

Market Cap

772.8M

Sector

Health Care

ML Signal

HOLD

Logo SunOpta Inc.

STKL

SunOpta Inc.

HOLD

Current Price

$6.49

Market Cap

769.4M

ML Signal

HOLD

Company Overview

Basic Information
Metric
OMER
STKL
Founded
1994
1973
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Precious Metals
Sector
Health Care
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
772.8M
769.4M
IPO Year
2008
1999

Fundamental Metrics

Financial Performance
Metric
OMER
STKL
Price
$11.36
$6.49
Analyst Decision
Strong Buy
Buy
Analyst Count
5
3
Target Price
$32.50
$7.50
AVG Volume (30 Days)
1.1M
1.2M
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
98.15
186.67
EPS
N/A
0.13
Revenue
$29,868,000.00
$817,715,000.00
Revenue This Year
N/A
$6.84
Revenue Next Year
$165.26
$33.58
P/E Ratio
N/A
$49.85
Revenue Growth
N/A
12.99
52 Week Low
$2.95
$3.32
52 Week High
$17.65
$6.94

Technical Indicators

Market Signals
Indicator
OMER
STKL
Relative Strength Index (RSI) 51.57 68.41
Support Level $10.82 $6.43
Resistance Level $11.93 $6.52
Average True Range (ATR) 0.64 0.02
MACD 0.13 -0.03
Stochastic Oscillator 47.99 41.67

Price Performance

Historical Comparison
OMER
STKL

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

About STKL SunOpta Inc.

SunOpta Inc is a Canadian company that focuses on a healthy product portfolio. The company is a manufacturer for natural and private label brands and also produces its own proprietary brands, including SOWN, Dream, and West Life. The core of its product portfolio is a range of plant-based beverages, including oat, almond, soy, coconut, and rice milks and creamers, which have a favorable climate profile relative to traditional dairy milks in terms of lower carbon emissions and water usage. Their plant-based offerings include non-genetically modified, organic, and gluten-free products. The consumer products portfolio also includes protein shakes, teas, broths, and fruit snacks. Geographically, the company operates in U.S, Canada, and Others, out of which it derives maximum revenue from U.S.

Share on Social Networks: